ensysce.com - ENSC Company Long-Term Liabilities

ENSC (ensysce.com) - company brandmark

Ensysce Biosciences (ENSC) attracts leading biochemists by creating safe analgesics within an academic environment devoid of excessive formalism. This chart reflects that the asset value is 0.00. Ensysce Biosciences (ENSC) relies on an elite staff of toxicologists, focusing on US compliance. Patents for gastrointestinal activation of drugs serve as a business moat, although strict government oversight and lengthy clinical trials hinder development.

ENSC Ensysce Biosciences Company Long-Term Liabilities (07/04/2022 - 10/28/2026)

Ensysce Biosciences, Inc. (ENSC) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Performance Chart Ensysce Biosciences Inc.|ENSC - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Ensysce Biosciences|ENSC - Total Company Value
- book capitalization data:
Net Asset Value per Share Ensysce Biosciences|ENSC - Company Net Assets|Market Value to Book Value ensysce.com|ENSC - Company Total Assets
- debt and liquidity data:
Aggregate Debt to Equity Ensysce Biosciences|ENSC - Long-Term Debt to Capital|Short-Term Debt to Capital Ensysce Biosciences Inc.|ENSC - Company Debts|Debt to Net Assets Ratio Ensysce Biosciences|ENSC - Company Long-Term Debt|Company Current Liabilities Ensysce Biosciences
Comprehensive company analysis:Ensysce Biosciences (ENSC)
Original product of Ensysce Biosciences, Inc.

The business credit profile is determined by the balance between capital expenditures and debt load. This indicator aggregates all obligations with a maturity of over one year, reflecting the long-term financing strategy. For Ensysce Biosciences (ENSC), such funds are critical for bringing TAAP technology to the commercial market. It is essential for investors to weigh borrowing rates against potential future margins. The dynamics of the company's long-term borrowed funds allow for an assessment of default risk.

Competitor analysis for Ensysce Biosciences

Company Long-Term Loans and Borrowings indivior.com INDV|COLL: Company Long-Term Debts|CRON: Company Long-Term Liabilities|Company Long-Term Debt CGC|Long-Term Debt Canna Cabana|ACB - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings achievelifesciences.com|SKYE - Company Long-Term Debts|Long-Term Liabilities Anebulo Pharmaceuticals Inc (ANEB)|Company Long-Term Debts INCR (InterCure)|Nutriband Inc - Company Long-Term Debts|Company Long-Term Debt Nasus Pharma, Ltd. (NSRX)|IGC: Company Long-Term Loans and Borrowings|MIRA (mirapharmaceuticals.com) - Company Long-Term Debt|Flora Growth Corp (FLGC) - Company Long-Term Liabilities|Company Long-Term Debts IMCC (IM Cannabis Corp)|Long-Term Debt ADIL|Company Long-Term Debt Artelo Biosciences ARTL|Company Long-Term Indebtedness TTNP (titanpharm.com)|Company Long-Term Debt GNLN|INM - Long-Term Debt Volume|AKAN (Akanda Corporation) - Company Long-Term Liabilities|ENVB: Long-Term Debt|brightgreen.us - Company Long-Term Debt|hempaccoinc.com (HPCO) - Long-Term Debt Volume